Cognitive impairment is a common clinical complication in patients with hypertension and metabolic syndrome. Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) are common antihypertensive agents popularly used, but their relative effects on cognitive outcomes are ambiguous. The gene discussed is ACE; the disease is hypertensive disorder.